Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.12T
Market cap1.12T
Price-Earnings ratio
40.21
Price-Earnings ratio40.21
Dividend yield
0.57%
Dividend yield0.57%
Average volume
2.34M
Average volume2.34M
High today
$1,192.96
High today$1,192.96
Low today
$1,172.56
Low today$1,172.56
Open price
$1,177.85
Open price$1,177.85
Volume
500.91K
Volume500.91K
52 Week high
$1,292.65
52 Week high$1,292.65
52 Week low
$716.08
52 Week low$716.08

Stock Snapshot

Eli Lilly(LLY) stock is priced at $1,190.87, giving the company a market capitalization of 1.12T. It carries a P/E multiple of 40.21 and pays a dividend yield of 0.57%.

On 2026-09-28, Eli Lilly(LLY) stock traded between a low of $1,172.56 and a high of $1,192.96. Shares are currently priced at $1,190.87, which is +1.6% above the low and -0.2% below the high.

The Eli Lilly(LLY)'s current trading volume is 500.91K, compared to an average daily volume of 2.34M.

During the past year, Eli Lilly(LLY) stock moved between $716.08 at its lowest and $1,292.65 at its peak.

During the past year, Eli Lilly(LLY) stock moved between $716.08 at its lowest and $1,292.65 at its peak.

LLY News

Investing.com 2h
JPMorgan raises Eli Lilly stock price target on incretin strength - Investing.com

...

JPMorgan raises Eli Lilly stock price target on incretin strength - Investing.com
The Motley Fool 2h
Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly?

Investing in a top company can offer safety and stability, but oftentimes, the potential upside can also be limited. Take Eli Lilly (LLY +0.13%) as a prime exam...

Could This Mid-Cap GLP-1 Stock Be a Better Buy Than Eli Lilly?
TipRanks 4h
Eli Lilly price target raised to $1,500 from $1,400 at JPMorgan

JPMorgan raised the firm’s price target on Eli Lilly (LLY) to $1,500 from $1,400 and keeps an Overweight rating on the shares ahead of the Q3 report on October...

Analyst ratings

84%

of 32 ratings
Buy
84.4%
Hold
9.4%
Sell
6.3%

More LLY News

TipRanks 4h
Eli Lilly launches ‘Lilly Change the Course Commitment’

Eli Lilly (LLY) and Company is launching the Lilly Change the Course Commitment, a new global health initiative that aims to achieve parity in patients treated...

TipRanks 16h
Nektar awarded $90M in Eli Lilly breach of contract case

Nektar (NKTR) in 2023 filed a complaint in the U.S. District Court for the Northern District of California against Eli Lilly (LLY) alleging, among other claims,...

24/7 Wall St. 20h
Eli Lilly Just Won FDA Approval for a Once Weekly Insulin and the Stock Is Knocking on $1,200

Investing Eli Lilly Just Won FDA Approval for a Once Weekly Insulin and the Stock Is Knocking on $1,200 The FDA just handed Eli Lilly a new diabetes approval, b...

Eli Lilly Just Won FDA Approval for a Once Weekly Insulin and the Stock Is Knocking on $1,200
Simply Wall St 2d
Eli Lilly Stock Trades At A Discount After Its 439% Run

has turned into one of the most closely watched pharmaceutical stocks, with the share price at US$1,183.46 and a very large 5 year gain putting fresh focus on w...

Eli Lilly Stock Trades At A Discount After Its 439% Run
Nasdaq 2d
Lilly Cut an Obesity Drug -- but the Move Shows How High Its Bar Has Become

Key Points Eli Lilly was second to market with a GLP-1 drug, but it quickly became the industry leader. The company recognizes that patents will only protect...

Lilly Cut an Obesity Drug -- but the Move Shows How High Its Bar Has Become
TipRanks 3d
Lilly Targets Pediatric Obesity With New Tirzepatide Trial: What Investors Should Watch

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. The phase 3 ADVANCE-SURMOUNT-KIDS study, officially titled “Efficacy, Safety,...

Benzinga 3d
Eli Lilly Did Breach Implied Covenant of Good Faith With Nektar Therapeutics, Jury Funds

A federal jury in California has awarded Nektar Therapeutics Inc. (NASDAQ:NKTR) $90 million in damages, finding that Eli Lilly and Co. (NYSE:LLY) breached the i...

Eli Lilly Did Breach Implied Covenant of Good Faith With Nektar Therapeutics, Jury Funds

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.